Clinical trials: SARS-COV-2 Infections
Covid19, Pneumonia
Coronavirus: Ventilator Outcomes Using Artificial Intelligence Chest Radiographs & Other Evidence-based Co-variates
We will determine ventilator outcomes to Coronavirus Infectious Disease 2019 (COVID-19) using artificial Intelligence with inputs of chest radiographs and other evidence-based co-variates.
- Trial name
- COVID VOICE (NCT04855539)
- Where
- 3 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- King's College Hospital NHS Trust
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19 Infection, Malignant Solid Neoplasm
Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors
This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as…
- Trial name
- NCT04447222
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
- Where
- United States
- Volunteers
- 1,242 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Covid19
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19
APN01 is a soluble recombinant form of the human angiotensin-converting enzyme 2 (rhACE2) that is currently under development as a therapy for corona-virus-disease 2019 (COVID-19).
- Trial name
- NCT05065645
- Testing
- Angiotensin Converting Enzyme 2, Sodium chloride
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Apeiron Biologics
Covid19
Study Evaluating the Olfactory Recovery of Anosmia Post COVID-19 by Olfactory Rehabilitation Assisted by Web-application
Anosmia is a symptom present in 40 to 80% of patients and usually only lasts 1 to 2 weeks. However, in nearly one in five patients, it can last beyond or even several months with consequences in terms of undernutrition and…
- Trial name
- COVIDANOSMIA (NCT04806880)
- Testing
- Web-application
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Weprom
COVID, Drug Effect
New Antiviral Drugs for Treatment of COVID-19
Background: In December 2019, SARS-CoV-2 was isolated on Vero E6 and Huh7 cell lines after an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province, China.
- Trial name
- NCT04392427
- Testing
- Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Covid19, SARS (Severe Acute Respiratory Syndrome)
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for COVID-19 patients in the intensive care unit
- Trial name
- NCT04853927
- Testing
- Proxalutamide
- Where
- Brazil
- Sponsor
- Applied Biology, Inc.
Acute Respiratory Failure, Covid19
Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients
To evaluate the use of Life2000® Ventilator, a novel proportional open ventilation system in critical care use of acute onset of respiratory failure (ARF) and mild to moderate forms of acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04581161
- Testing
- Life2000® Ventilator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Covid19
Electrocardiographic QRS Axis Shift ,Rotation and COVİD-19
In patients with coronavirus disease (COVID-19), severe dyspnea is the most dramatic complication.Severe respiratory difficulties may include electrocardiographic frontal QRS axis rightward shift (Rws) and clockwise rotation…
- Trial name
- NCT04698083
- Testing
- Electrocardiography ,Tomographic imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara Education and Research Hospital
Covid19
TOcilizumab and Covid-19 : Risk of Severe INfection
SARS-CoV2 is responsible for a pandemic that has been evolving for approximately 18 months. The virus' capacity for dissemination and its virulence are responsible for significant morbidity and mortality.
- Trial name
- TOCSIN (NCT05017441)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Immune Response of Asymptomatic EHPAD Employees Infected With COVID-19
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris France (EHPAD), where the virus had been circulating actively in March and April 2020.
- Trial name
- SERASYMPTO (NCT05128656)
- Testing
- serology
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sars-CoV2
COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits
Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation.
- Trial name
- CRASH (NCT04412473)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19
Post Covid Syndrome: Clinical Pattern and Functional Assessment
Aim(s) of the Research : 1. Identify post covid symptoms 2. prevalance of post covid syndrome among survivours
- Trial name
- NCT04561141
- Volunteers
- 85 people
- Sponsor
- Assiut University
Coronavirus
Clinical Characteristics and Prognostic Factors of Patients With COVID-19
As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of…
- Trial name
- NCT04328454
- Testing
- retrospective analysis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai 10th People's Hospital
Covid19
A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
COVID19-associated disease may have different clinical aspects classified in 3 stages. Some patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve toward a more severe stage 2b or 3 (acute…
- Trial name
- INFLAMMACOV (NCT04424056)
- Testing
- Anakinra +/- Ruxolitinib (stages 2b/3), Anakinra and Ruxolitinib (Advanced stage 3), Tocilizumab +/- ruxolitinib (stages 2b/3)
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
COVID-19
Protecting Native Families From COVID-19
The goal of this study is to increase and hasten testing among those with COVID-19 symptoms and improve adherence to recommended strategies following positive test results in high-risk groups in the White Mountain Apache and…
- Trial name
- NCT04765475
- Testing
- Motivational Interviewing, COVID-19 Symptom Monitoring System, Motivational Interviewing and COVID-19 Symptom Monitoring System
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cardiovascular Diseases
Effects of COVID-19 Pandemic on a Health Care System: Case Study of the CirculatORy System in LiThuania
Coronavirus disease of 2019 (COVID-19) affected the health care systems all around the world. The collateral damage of the pandemic on the cardiovascular (CV) care and CV mortality has been noticed and reported early.
- Trial name
- COVID-COR-LT (NCT05021575)
- Testing
- Data collection on outpatient care, Data collection on hospitalisation, Data collection on cardiovascular mortality
- Where
- 3 sites in Lithuania
- Volunteers
- 839,678 people
- Sponsor
- Vilnius University
Covid19, Covid-19 ARDS
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04678739
- Testing
- Remdesivir, Tocilizumab
- Where
- 4 sites in Bangladesh
- Volunteers
- 205 people
- Sponsor
- M Abdur Rahim Medical College and Hospital
Post Acute Sequelae Covid-19 Hyposmia
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
- Trial name
- NCT05970731
- Testing
- Beclomethasone, Microsponge
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Chronic Stress, Chronic Fatigue
The Effect of the Human Regenerator Jet Device on the Quality of Life of Adult Individuals [HR-QoL]
This cross-over single-blinded study aims to evaluate the effect of a novel cold atmospheric plasma jet-producing device, the Human Regenerator Power Jet device, for individuals who suffer from chronic stress, chronic pain…
- Conditions
- Chronic Stress, Chronic Fatigue, Chronic Pain, Post-COVID / Long-COVID
- Trial name
- HR-QoL (NCT07279272)
- Testing
- Cold Atmospheric Plasma, Atmospheric Air
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University of Athens
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.